Zoladex/Zoladex LA Indications/Uses

Zoladex: Prostate cancer: ZOLADEX 3.6 mg is indicated in the management of prostate cancer suitable for hormonal manipulation.
Breast cancer: ZOLADEX 3.6 mg is indicated in the management of breast cancer in premenopausal and perimenopausal women suitable for hormonal manipulation.
Endometriosis: In the management of endometriosis, ZOLADEX 3.6 mg alleviates symptoms, including pain, and reduces the size and number of endometrial lesions.
Endometrial thinning: ZOLADEX 3.6 mg is indicated for the prethinning of the uterine endometrium prior to endometrial ablation or resection.
Uterine fibroids: In conjunction with iron therapy in the haematological improvement of anaemic patients with fibroids, prior to surgery.
Assisted reproduction: Pituitary downregulation in preparation for superovulation.
Zoladex LA: Prostate cancer: ZOLADEX LA 10.8 mg is indicated in the management of prostate cancer suitable for hormonal manipulation.
Endometriosis: ZOLADEX LA 10.8 mg is indicated in the management of endometriosis including alleviation of symptoms, such as pain, and reduction in the size and number of endometrial lesions.
Uterine fibroids: ZOLADEX LA 10.8 mg is indicated in the management of fibroids including shrinkage of lesions, improvement in the patient's haematological status and reduction of symptoms, such as pain. It can be used as an adjunct to surgery to facilitate the operative technique and reduce operative blood loss.
Breast cancer: ZOLADEX LA 10.8 mg is indicated in the management of estrogen-receptor-positive breast cancer in premenopausal women.